Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) shares declined 4.11 percent to close at $14.71 a share Monday. The stock traded between $14.49 and $14.87 on volume of 2.37 million shares traded. Analysts at B. Riley have recently downgraded the company’s rating to "sell" from "neutral". Shares of Allscripts have gained approximately 55.0 percent over the past year.
Find out more about Allscripts including full access to the free equity report at:
www.RDInvesting.com/MDRX
Sanofi SA (NYSE: SNY) shares declined 0.10 percent to close at $51.99 a share Monday. The stock traded between $51.97 and $52.31 on volume of 2.95 million shares traded. Analysts at JPMorgan have recently downgraded the company’s rating to "neutral" from "overweight". Shares of Sanofi have gained approximately 8.0 percent over the past year.
Find out more about Sanofi including full access to the free equity report at:
www.RDInvesting.com/SNY
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares declined 8.17 percent to close at $18.77 a share Monday. The stock traded between $17.76 and $19.60 on volume of 4.23 million shares traded. Analysts at Citigroup have recently downgraded the company’s rating to "sell" from "neutral". Shares of Sarepta Therapeutics have fallen approximately 35.0 percent over the past year.
Find out more about Sarepta Therapeutics including full access to the free equity report at:
www.RDInvesting.com/SRPT
Tetralogic Pharmaceuticals Corp. (NASDAQ: TLOG) shares declined 1.34 percent to close at $10.34 a share Monday. The stock traded between $9.50 and $11.24 on volume of 167,169 shares traded. Analysts at Needham have recently initiated coverage on the company with a "buy" rating and a price target of $16.00. Shares of Tetralogic Pharmaceuticals have gained approximately 45.0 percent since its IPO.
Find out more about Tetralogic Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/TLOG
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]